Full-Length Recombinant Human SCF$^{1-165}$ Is More Thermostable than the Truncated SCF$^{1-141}$ Form

Yui-Ping Weng$^{1,2,*}$, Wen-Yen Ku$^{1,2}$, Ming-Han Wu$^1$, Ya-li Tsai$^1$, Chi-Yu Chen$^1$, Chun-An Kuo$^2$, Lynn L. H. Huang$^3$

1 Graduate Institute of Biological Science and Technology, Chung Hwa University of Medical Technology, Tainan, Taiwan, 2 Department of Biological Science and Technology, Chung Hwa University of Medical Technology, Tainan, Taiwan, 3 Institute of Biotechnology, Cheng Kung University, Tainan, Taiwan

Abstract

Human stem cell factor initiates a diverse array of cellular responses, including hematopoiesis, cell proliferation, differentiation, migration and survival. To explore the relationship between its structure and function, we produced recombinant soluble human stem cell factor$^{1-165}$ (wild type) and human stem cell factor$^{1-141}$ (C-terminal truncated) in a yeast expression system and compared their biological activities and thermal stabilities. The biological activity of the two proteins was measured as a function of TF-1 cell viability and effects on downstream signaling targets after incubation. We found that these proteins enhanced cell viability and downstream signaling to a similar extent, in a dose-dependent manner. The biological activity of recombinant human stem cell factor$^{1-165}$ was significantly greater than that of recombinant human stem cell factor$^{1-141}$ after heating the proteins (100 ng/mL) at 25–110 °C for 10 minutes (P<0.05 for all temperatures). In addition, circular dichroism spectral analysis indicated that β-sheet structures were altered in recombinant human stem cell factor$^{1-141}$ but not recombinant human stem cell factor$^{1-165}$ after heating at 90°C for 15 or 30 min. Molecular modeling and limited proteolytic digestion were also used to compare the thermostability between human stem cell factor$^{1-165}$ and human stem cell factor$^{1-141}$. Together, these data indicate that stem cell factor$^{1-165}$ is more thermostable than stem cell factor$^{1-141}$.

Introduction

Human stem cell factor (hSCF) is a glycoprotein cytokine that induces Kit activity. The effects of SCF are exerted through at least 4 intracellular pathways and involve Src family members, phosphatidylinositol-3-kinase, the Janus family of protein tyrosine kinases (Jak), and the Ras-Raf-mitogen activated protein (MAP) kinase cascade. These pathways mediate a number of cellular processes, including gene transcription, proliferation, differentiation, survival, metabolic homeostasis, melanin pigmentation, development, and cell migration [1–10].

SCF is expressed as two different isoforms composed of 220 and 248 amino acids. These membrane-associated proteins are generated via alternative splicing of the same RNA transcript [11], the latter of which includes a proteolytic cleavage site in exon six. Cleavage at this site releases the extracellular portion of the protein from the membrane [12,13], becoming the soluble form of SCF. Both the membrane-associated and soluble (SCF$^{1-165}$) forms are biologically active [14]. The core of the protein required for activity comprises residues 1–141 and is reported to bind and activate the receptor Kit [15–17]. The function of the C-terminal domain of SCF$^{1-165}$ is not yet known. Soluble SCF functions as a non-covalently associated homodimer, but the majority of SCF exists as a monomer under physiological conditions [18]. Each SCF monomer contains two intra-chain disulfide bridges (Cys4–Cys89 and Cys43–Cys138) that are required for its activity [16]. SCF monomers can be glycosylated at residues Asn65, Asn72, and Asn120 [13,19].

SCF is involved in a wide range of biological processes and is commercially available. These factors have led to the experimental use of this protein and make it an attractive candidate for further clinical and industrial applications. In this study, we analyze the biological function and compare the thermostability of recombinant SCF$^{1-165}$ and SCF$^{1-141}$ proteins by assessing their ability to enhance the viability of human leukemia cells and mediate downstream biochemical pathways. The C-terminal sequence present in SCF$^{1-165}$ (N-STLSPKDSVSTKKPPMLPPVA-C) but absent in SCF$^{1-141}$ is predicted to function as a flexible loop. However, the possible role of this protein domain in the biological function or thermostability of SCF$^{1-165}$ has not been well characterized.

In a previous study, Wen et al. [20], explored the activity of a glucanase with a 10 kDa deletion from the C-terminus and found that this truncated protein possessed more industrially-favorable properties than the full-length protein, including higher specific activity (4–5-fold increase) and greater thermostolerance. Strikingly, the truncated enzyme retained 80% of its activity even after being boiled for 10 minutes. In the present study, we explore whether the absence of the C-terminal sequence of SCF$^{1-165}$ confers similar properties on SCF$^{1-141}$. We use computer
modeling to simulate the structures of these 2 forms of the SCF protein and to calculate their thermal stability, allowing further comparison of their thermal stabilities [21–23]. Limited proteolytic digestion was also performed to explore the structural thermostability of these 2 forms of the SCF protein [24–25].

**Materials and Methods**

**Construction of recombinant human SCF expression vectors**

The linear DNA fragments encoding rhSCF1–165 and C-terminus truncated rhSCF1–141 were obtained from pCR4-TOPO (Invitrogen, Grand Island, NY USA) by PCR performed with a sense primer (5'- ATC GATG GAA GGG ATC AAC AGG GAT CGT -3') and anti-sense primers (3'SCF1–165 [5'- TCA GGG TGC AAC AGG GGG TAA CAT AAA 3'] or 3'SCF1–141 [5'- TCA AGA AAC ACA ACA ATC AGT TTC 3']) in which the Cla I and Xho I sites were introduced. The resulting rhSCF1–165 or rhSCF1–141 cDNA fragment was double digested with Cla I and Xho I (TaKaRa, Japan), purified by agarose gel electrophoresis, and cloned into pPICZC/h to yield pPICZC/hSCF1–165 or pPICZC/hSCF1–141. The procedures for small scale preparation of plasmid, digestion with restriction enzymes, ligation, and transformation all followed the standard methods. PCR was carried out using 2.5 U of Taq DNA polymerase (TaKaRa) in a final volume of 50 μl using the following conditions: 95°C for 10 min, 30 cycles (95°C for 60 s, 55°C for 30 s, and 72°C for 60 s) and a final extension at 72°C for 7 min.

**Electroporation of X33 and screening for recombinant strains**

The plasmids pPICZC/hSCF1–165 and pPICZC/hSCF1–141 were linearized with Sac I and transformed into yeast Pichia pastoris strain X33 using the electroporation method according to the supplier's instruction. Transformed cells were then plated onto YPDS containing 100 μg/mL zeocin and incubated at 30°C for at least 3 days. Single colonies were transferred simultaneously onto Minimal Methanol Medium (MM) and Minimal Dextrose Medium (MD) plates to test their methanol utilization phenotype. The MM and MD plates were incubated at 30°C for 2 days to distinguish between the Mut<sup>+</sup> and Mut<sup>−</sup> recombinants. Recombinant strains containing the SCF<sup>1–141</sup> or SCF<sup>1–165</sup> gene were screened by colony PCR. Several clones with the Mut<sup>−</sup> phenotype that expressed the maximal levels of hSCF<sup>1–165</sup> or hSCF<sup>1–141</sup> were chosen in small-scale expression and stored in YPD containing 10% FBS as controls (n = 6).

**Overexpression of rhSCF<sup>1–141</sup> or rhSCF<sup>1–165</sup> in yeast**

Selected colonies of zeocin-resistant transformants were inoculated into 5 mL of Yeast Extract-Peptone-Dextrose (YPD) broth (1% yeast extract, 2% peptone, 2% glucose) containing 100 μg/mL zeocin at 30°C, grown to stationary phase, and then inoculated to 300 mL of Buffered Glycerol-complex Medium (BMGY). After incubation at 30°C with shaking at 100 rpm, the cells were centrifuged at 3000 x g for 10 min and harvested at 1000 mL of Buffered Methanol-Complex Medium (BMMMY) to OD<sub>600</sub> of 1. The cells were allowed to grow for 72 h at 30°C, and methanol was added every 24 h to a final concentration of 0.5–1% (v/v) to induce expression of the target protein. After 72 h, cells were removed by centrifugation at 3000 x g for 5 min, and the supernatants were collected. For recombinant protein detection, the supernatants were analyzed by 15% (w/v) SDS-PAGE. Secretion of the mature protein is expected to result in protein glycosylation. The construct contains the yeast α-factor promoter, which directs the secretion of rhSCF, followed immediately by the sequence for mature rhSCF beginning with the glutamate at amino acid position 1.

**Purification of rhSCF<sup>1–141</sup> and rhSCF<sup>1–165</sup> from yeast**

Culture supernatants were applied to a phenyl column (GE Healthcare, Piscataway, NJ USA) pre-equilibrated with buffer (0.01 M sodium phosphate, 1.5 M ammonium sulfate; pH 6). After loading, the column was washed with the same buffer and eluted with a linear gradient of 1.5–0 M ammonium sulfate in the same buffer. The active fractions (5 mL) were collected using a flow rate of 60 mL/h. After centrifugation at 20 000 x g for 30 min at 4°C, each sample was loaded onto a Q-Sepharose (2.6 × 20 cm) column pre-equilibrated with 0.01 M sodium phosphate buffer, pH 8 using an AKTA explorer 10S system. Fractions containing rhSCF were eluted with the same buffer containing 1 M NaCl and collected at a flow rate of 120 mL/h. The eluted solution containing rhSCF was concentrated using filter devices with centrifugation at 3000 x g for 60 min at 4°C. Concentrated solutions containing rhSCF were loaded onto Sephadex G-75 columns pre-equilibrated with phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na<sub>2</sub>PO<sub>4</sub> and 1.47 mM KH<sub>2</sub>PO<sub>4</sub> pH 7.4). Fractions containing rhSCF were collected and analyzed by SDS-PAGE using Coomasie brilliant blue staining. Western blotting with goat anti-His antibody (1:1000) (Clontech, Mountain View, CA USA) was used to detect rhSCF with 6-His tag overexpressed from culture supernatant derived from *pichia* transformants carry hSCF<sup>1–141</sup>-6His tag or hSCF<sup>1–165</sup>, 6His tag. The amount of purified rhSCF was determined by BCA protein analysis using bovine serum albumin (BSA) as a standard. Aliquots of recombinant proteins were stored in PBS buffer at −20°C and were thawed at 4°C before use in cell viability assays or Western blot analysis for downstream signaling effect.

**Cell lines**

The human leukemia cell line TF-1 was purchased from Bioresource Collection and Research Center (Hsinchu, Taiwan) and grown in RPMI-1640 supplemented with 10% fetal bovine serum and 1–5 ng/mL recombinant IL-3. Cells were cultured at 37°C in a humidified chamber containing 5% CO<sub>2</sub>.

**Cell viability assay**

Cell viability was measured using the Alamar blue assay (Invitrogen, Grand Island, NY USA) according to the manufacturer's instructions. Briefly, 10 000 TF-1 cells were plated into each well of a 96-well plate, followed by incubation at 37°C in a CO<sub>2</sub> chamber with media changes every 3 days. Various concentrations of rhSCF were added to the wells. After 5 days, 10 μL of Alamar blue was added to each well and incubated at 37°C for 24 h. The cell viability (%) of controls was calculated using the formula as follows: [rhSCF-treated sample (OD<sub>600</sub>) − OD<sub>600</sub>untreated sample (PBS) (OD<sub>600</sub> untreated sample) ×100] Cell suspensions were maintained in 10% FBS as controls (n ≥ 6).

**Effects of rhSCF<sup>1–141</sup> and rhSCF<sup>1–165</sup> on downstream signaling targets MAPK and Akt**

Molecules involved in downstream signaling regulation of rhSCF were examined using Western blot analysis. TF-1 cells were grown at 3 × 10<sup>5</sup> cells on 10 cm plates, washed, and starved in 0.5% fetal bovine serum (FBS) medium for 20 to 24 hours, then stimulated with recombinant IL-3 and various concentrations of rhSCF. Western blot analysis, cells were harvested and lysed with lysis buffer (1% NP-40, 50 mmol/L Tris-HCl [pH 7.4],
0.25% sodium deoxycholate, 150 mmol/L NaCl, 1 mmol/L EGTA, 1 mmol/L PMSF, 1 mg/mL leupeptin, 1 mmol/L Na3VO4, 1 mmol/L NaF). The unsolubilized material was removed by centrifugation for 10 minutes at 13,000 rpm. Samples were electrophoresed by SDS-PAGE and then transferred onto a PVDF membrane (Immobilon-P; Millipore GmbH, Eschborn, Germany). The membrane was blocked with 5% nonfat dry milk powder in phosphate-buffered saline with 0.1% Tween-20 for 1 hr at room temperature. After blocking the membrane was incubated with the primary antibody (Antibodies against phospho-MAPK(Thr202/Tyr204), MAPK, phospho-Akt(Ser473), and Akt were all purchased from New England BioLabs (Beverly, MA); β-actin was from Sigma (Sigma-Aldrich, St Louis, MO). The corresponding HRP-conjugated secondary antibody was applied to the membrane for 1 hr to highlight the specific signal. HRP substrate (Millipore, Billerica, MA, USA) was added onto blot membrane to show the pattern, and images were acquired using the LAS-3000 imaging system (Fujiﬁlm, Japan). Blot images were quantiﬁed using Multi-Gauge software (Fujiﬁlm). Results are expressed as the ratio of intensity of the protein of interest to that of β-actin from the same sample.

**Circular dichroism (CD) spectroscopy**

The thermal stability of the wild-type and truncated forms of rhSCF was determined by measuring temperature-induced changes in ellipticity. CD spectroscopic studies were carried out using an AVIV CD400 spectrometer (Aviv Biomedical, Inc. Lakewood Township, NJ USA) at temperatures of 25–95°C. Samples of puriﬁed rhSCF1–141 or rhSCF1–165 (300 μg/mL) were analyzed in 100 mM sodium phosphate buffer (pH 7.0). Spectra were collected from 190 to 250 nm in 0.5 nm increments, and each spectrum was blank-collected and smoothed using the software package provided with the instrument. Sample cells with 2 mm pathlengths were used for far-UV CD analysis. The spectra were measured 3 times at each temperature. The molar ellipticity $\theta$ of each sample was determined using the expression $\theta = \theta_{obs} \times M_r / (10 \times c \times l)$, where $\theta_{obs}$ is the observed ellipticity (millidegrees), $M_r$ is the molecular weight of the protein, $c$ is protein concentration (mg/mL), and $l$ is the pathlength (cm).

For use as controls, recombinant SCF1–141 and SCF1–165 proteins were resuspended in 100 mM sodium phosphate buffer (pH 7.0) at 25°C. Samples of puriﬁed rhSCF1–141 or rhSCF1–165, each 15 μg, was incubated with trypsin at 25°C or 90°C for 10 minutes, or preheated at 90°C for 10 minutes, 90 minutes, or 120 minutes and then treated with trypsin for 10 minutes at 25°C or 90°C. After digestion times indicated, samples were taken and subjected to SDS-PAGE analysis. The digestion products were then separated by SDS-PAGE on a 15% gel and stained with Coomassie blue.

**Statistical analysis**

Continuous data are presented as the mean ± SD. The dose-dependent relationship between concentration of rhSCF and cell viability was measured using Spearman correlation coefficient (rs). The differences in cell viability between the 2 treatment groups (rhSCF1–141 vs. rhSCF1–165) and the other factors (temperature and time) were detected using two-way analysis of variance (ANOVA) with interaction. Pairwise post-hoc tests using Bonferroni correction were applied if ANOVA findings were signiﬁcant. Statistical analyses were performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC). A two-tailed P<0.05 indicated statistical signiﬁcance.

**Results**

**Construction of the rhSCF expression vector**

Two variants of the hSCF gene, a full-length hSCF coding region (aa 1–165) and a truncated hSCF cDNA (aa 1–141), were constructed and inserted into the P. pastoris expression vector pPICZαC. In the recombinant plasmid, the hSCF gene was placed downstream of the α-factor promoter and leader sequences in the same ORF. Restriction enzyme analysis and DNA sequencing conﬁrmed that the rhSCF gene was correctly inserted into pPICZαC (Fig. 1A).

**Expression and characterization of rhSCF1–141 and rhSCF1–165 in P. pastoris**

The plasmids pPICZαC-rhSCF1–141 and pPICZαC-rhSCF1–165 were integrated into the alcohol oxidase promoter (AOX I) locus of the P. pastoris chromosome. Methanol induced the expression of the rhSCF1–141 and rhSCF1–165 proteins, appearing on SDS-PAGE as a double band with molecular weights of about 21 and 24 kDa, respectively (Figs. 1B). Purification of rhSCF1–141 and rhSCF1–165

Fractions eluted from phenyl column chromatography containing recombinant rhSCF1–141 or rhSCF1–165 was further puriﬁed by Q-Sepharose Fast Flow and Sephadex G-75 column chromatography. SDS-PAGE of the resulting eluent revealed 2 major bands with molecular weights of approximately 21 and 24 kDa, corresponding to puriﬁed rhSCF1–141 and rhSCF1–165, respectively (Figure 1C). The estimated molecular weights of SCF1–141 and SCF1–165 (based on amino acid sequences) are 15–16 and
18–19 kDa, respectively. Thus, the bands at about 21 kDa (Figure 1 C, lanes 1 and 2 upper band) and 24 kDa (Figure 1C, lanes 3 and 4) are likely the glycosylated forms of rhSCF1–141 or rhSCF1–165. Purified rhSCF1–141 still had a minor band around 14 kDa might be the non-glycosylated form (Fig 1C, lanes 1 and 2 lower band). Both are consistent with the result as shown in the western blots using anti-His antibody (Figure 1 D).

Figure 1. The expression and purification of rhSCF1–141 and rhSCF1–165. (A) PCR analysis of pPICZaC-rhSCF1–141 (1011 bp) and pPICZaC/SCF1–165 (1083 bp) using 5′ AOX I and 3′ AOX I primers (arrow). (B) Coomassie blue-stained SDS-PAGE of rhSCF1–141 and rhSCF1–165 overexpressed from Pichia culture supernatants. Lane M: molecular weight markers. Numbers above the lanes represent hours after methanol induction. Arrows indicate the overexpressed rhSCF1–141 or rhSCF1–165 (C) Silver-stained 15% SDS–PAGE of purified rhSCF1–141 and rhSCF1–165 produced in P. pastoris. Lane M, molecular weight markers. Lanes 1 and 2, purified rhSCF1–141 (200 and 100 ng, respectively); Lanes 3 and 4, purified rhSCF1–165 (20 and 50 ng, respectively). (D) Western blot analysis of rhSCF1–141-6His and rhSCF1–165-6His from culture supernatants. The recombinant proteins were 6xHis tagged and detected with anti-His antibodies. doi:10.1371/journal.pone.0103251.g001

Viability of cells treated with rhSCF1–141 and rhSCF1–165

SCF has been reported to play a role as a survival factor in myeloid cells, preventing cell death via c-Kit [26]. To determine whether SCF treatment affected the viability of TF-1 cells, cell viability assays were performed. rhSCF1–141 and rhSCF1–165 had a dose-dependent positive effect on human TF-1 cell viability (SCF 1–141, r = 0.838, P < 0.001; rhSCF 1–165, r = 0.825, P < 0.001). TF-1 cells were incubated with 10, 20, 100, or 500 ng/mL rhSCF1–141 or rhSCF1–165. Cells treated with 100 ng/mL showed significant differences in viability between rhSCF1–141 and rhSCF1–165 (Figure 2) (P = 0.047).
Effect of rhSCF\textsuperscript{1–141} and rhSCF\textsuperscript{1–165} on downstream signaling pathways involving MAPK and AKT

To further establish the biological activity of rhSCF\textsuperscript{1–141} and rhSCF\textsuperscript{1–165}, we investigated the expression and phosphorylation of MAPK and AKT in cells treated with rhSCF\textsuperscript{1–141} and rhSCF\textsuperscript{1–165} using Western blotting. Our data show that the levels of pMAPK and pAkt increased in a concentration-dependent manner with either rhSCF\textsuperscript{1–141} or rhSCF\textsuperscript{1–165} treatment (Figure 3A, B). Relative MAPK expression was significantly higher in cells treated with rhSCF\textsuperscript{1–165} than in those treated with rhSCF\textsuperscript{1–141} at concentrations of 0, 10, 20, and 100 ng/mL. The relative levels of p-Akt were significantly higher in cells treated with rhSCF\textsuperscript{1–165} than those treated with rhSCF\textsuperscript{1–141} at concentrations of 20, 100, and 500 ng/mL.

Thermostability of rhSCF\textsuperscript{1–165} and rhSCF\textsuperscript{1–141}

We investigated and compared the thermostability of rhSCF\textsuperscript{1–141} and rhSCF\textsuperscript{1–165} at different temperatures. Two-way ANOVA showed a significant difference in viability between cells treated with rhSCF\textsuperscript{1–165} and rhSCF\textsuperscript{1–141} (P < 0.001) and between those treated at different temperatures (P < 0.001). After Bonferroni correction for multiple comparisons, the viability of cells treated with rhSCF\textsuperscript{1–165} was significantly higher than that of cells treated with rhSCF\textsuperscript{1–141} at all temperatures tested (Figure 4A). These data suggest that the biological activity of rhSCF\textsuperscript{1–141} is less than that of SCF\textsuperscript{1–165} after heat treatment.

Thermostability of rhSCF\textsuperscript{1–165} and rhSCF\textsuperscript{1–141} over time

To determine how long the effect of treatment with 100 ng/mL of rhSCF\textsuperscript{1–141} or rhSCF\textsuperscript{1–165} could be maintained at 90°C, we performed cell viability assays over a time course up to 150 minutes (Figure 4B). The results of two-way ANOVA showed both the protein used for treatment and the time of heat treatment significantly affected cell viability (both P < 0.001). Our results indicate that the differences in viability between cells treated with rhSCF\textsuperscript{1–165} and rhSCF\textsuperscript{1–141} varied with the time of heat treatment (P = 0.007). Using Bonferroni correction for multiple comparisons, we observed that the viability of cells treated up to 30 minutes was significantly higher in those treated with rhSCF\textsuperscript{1–165} than with rhSCF\textsuperscript{1–141} (P = 0.002).

CD spectrometric analysis of rhSCF\textsuperscript{1–165} and rhSCF\textsuperscript{1–141}

Structural changes in the wild-type (full-length) SCF\textsuperscript{1–165} and truncated SCF\textsuperscript{1–141} proteins were analyzed using CD spectroscopy. The far-UV (190–250 nm) CD spectra of full-length and truncated SCF proteins were monitored at temperatures ranging from 25–90°C (Figures 5A and 5B). The CD spectra of rhSCF\textsuperscript{1–165} that was heat-treated at 70°C for 10 min and at 90°C for 15–60 min were identical at 195 nm. The shapes of the bands at 195 nm were similar to those of the unheated control. Conversely, rhSCF\textsuperscript{1–141} treated at 90°C for 15 or 30 minutes had negative bands at 195 nm, suggesting that the β-sheet structures had changed as a result of thermal denaturation.

Molecular modeling

A search for the 3D structure of SCF in the protein data bank (PDB) revealed that only the 3D structure of SCF\textsuperscript{1–141} has been resolved by the X-ray diffraction method. Therefore, our molecular simulation strategy used SCF\textsuperscript{1–141} as the template. Because the C-terminus of SCF\textsuperscript{1–165} has extra amino acids (142 to 165), simulation software was used to predict its structure. After completing the simulation, we calculated the potential energy (Figure 6A) and the interatomic discrete distance (Root Mean Square Deviation, RMSD) and compared those values between SCF\textsuperscript{1–165} and SCF\textsuperscript{1–141} (Figure 6B, C, and D). We found that after heating 70°C, and 90°C, the discrete interatomic distance of SCF\textsuperscript{1–165} was smaller than that of SCF\textsuperscript{1–141}, indicating that recombinant SCF\textsuperscript{1–165} has greater thermal stability than recombinant SCF\textsuperscript{1–141}. A snapshot of the temperature-induced structural changes in SCF\textsuperscript{1–141} is presented in Figure 6E.

Limited proteolytic digestion

We used limited proteolytic digestion to investigate the structural stability when digest proteins in their native or denatured configuration. As shown in Figure 7, rhSCF\textsuperscript{1–141} degrades faster than rhSCF\textsuperscript{1–165} and is more susceptible to trypsin.
digestion, indicating that SCF[1–165] is more thermostable than SCF[1–141].

Discussion

Both rhSCF[1–141] and rhSCF[1–165] enhanced TF-1 cell viability in a dose-dependent manner. The biological activity of rhSCF[1–165] (100 ng/mL) was significantly greater than that of rhSCF[1–141] after 10 minutes of heat treatment at 25, 50, 70, 90, and 110°C and after heat treatment at 90°C for 0, 2, and 30 minutes. In addition, circular dichroism spectral analysis indicated that β-sheet structures in rhSCF[1–141] but not rhSCF[1–165] changed after 15 or 30 minutes of incubation at 90°C. All of these data indicate that SCF[1–165] is more heat-stable than SCF[1–141].

The relationship between SCF structure and function has been studied by comparing the activity of a variety of deletion mutants [17], including proteins with missing segments, N- or C-terminal truncations, and disulfide bond alterations. Proliferation and receptor binding activity were found to be deficient in mutants with deletions in or near the disulfide bonds. Forms that included the full length of the extracellular domain were observed to be fully

Figure 3. Effects of rhSCF[1–141] and rhSCF[1–165] on downstream signaling targets MAPK and Akt. Cells were incubated with rhSCF[1–141] or rhSCF[1–165] in PBS (pH 7.4) at the concentrations indicated. A and B are Western blots using the indicated antibodies. Similar results were obtained in 3 independent experiments. C is the quantitation results of the Western blots shown in A and B. doi:10.1371/journal.pone.0103251.g003

| Concentration: 0 ng/ml | p-MAPK | MAPK | p-Akt | Akt |
|------------------------|--------|------|-------|-----|
|                        | Mean + SD | P-value† | Mean + SD | P-value† | Mean + SD | P-value† | Mean + SD | P-value† |
| rhSCF[1–141]           | 0.029 ± 0.004 | 0.935 | 0.278 ± 0.032 | 0.007** | 0.026 ± 0.007 | 0.284 | 1.305 ± 0.028 | 1.000 |
| rhSCF[1–165]           | 0.033 ± 0.002 | 1.125 ± 0.182 | 0.040 ± 0.006 | 0.50 | 1.324 ± 0.068 | 1.000 |
| Concentration: 10 ng/ml |        |      |       |     |        |      |       |     |
| rhSCF[1–141]           | 0.607 ± 0.099 | 1.000 | 0.269 ± 0.053 | 0.007** | 0.062 ± 0.032 | 0.012* | 1.253 ± 0.079 | 1.000 |
| rhSCF[1–165]           | 0.539 ± 0.080 | 1.140 ± 0.182 | 0.376 ± 0.055 | 0.50 | 1.414 ± 0.298 | 1.000 |
| Concentration: 20 ng/ml |        |      |       |     |        |      |       |     |
| rhSCF[1–141]           | 0.941 ± 0.065 | 0.096 | 0.263 ± 0.057 | 0.013* | 0.151 ± 0.022 | 0.012* | 1.253 ± 0.079 | 1.000 |
| rhSCF[1–165]           | 1.467 ± 0.231 | 1.131 ± 0.215 | 0.580 ± 0.106 | 0.50 | 1.471 ± 0.356 | 1.000 |
| Concentration: 100 ng/ml |      |       |       |     |        |      |       |     |
| rhSCF[1–141]           | 1.046 ± 0.074 | 0.234 | 0.259 ± 0.026 | 0.020* | 0.172 ± 0.027 | 0.009** | 1.219 ± 0.066 | 1.000 |
| rhSCF[1–165]           | 1.460 ± 0.241 | 1.071 ± 0.235 | 0.627 ± 0.104 | 0.50 | 1.419 ± 0.334 | 1.000 |
| Concentration: 500 ng/ml |      |       |       |     |        |      |       |     |
| rhSCF[1–141]           | 1.121 ± 0.082 | 0.176 | 0.240 ± 0.068 | 1.000 | 0.197 ± 0.025 | 0.011* | 1.227 ± 0.065 | 1.000 |
| rhSCF[1–165]           | 1.626 ± 0.267 | 4.885 ± 6.691 | 0.636 ± 0.105 | 0.50 | 1.404 ± 0.319 | 1.000 |

†determined by independent t-test with Bonferroni correction

*P<0.05; **P<0.01; ***P<0.001.
active in both proliferation and receptor binding. Interestingly, E.coli-derived SCF\textsuperscript{1-141} was also fully active in both of these functions. Our results are in agreement with those of Langley et al. [17], indicating that \textit{P. pastoris}-derived SCF\textsuperscript{1-141} and SCF\textsuperscript{1-165} both enhance TF-1 cell viability.

We further established that rhSCF is biologically active by analyzing its effects on several downstream targets. Signaling
events downstream of the KIT receptor are well documented. In human hematopoietic cells, SCF induces activation and/or recruitment of major kinases such as PI3-kinase, Src kinases (Fyn and Lyn), and JAK2, and various adaptor molecules (Grb2, Grap, Vav, and CRKL) via their SH2 domain. These events result in various molecular associations via SH2, SH3, or PH domains, which in turn trigger the activation of different pathways. Among the signaling cascades that are activated are the Ras/Raf/MEK/MAPK and the PI3K/AKT/RPS6K pathways [27,28]. Our data show that the levels of pMAPK and pAkt increased in a concentration-dependent manner with either rhSCF 1–141 or rhSCF1–165 treatment, indicating that these recombinant proteins are biologically active (Figure 3). The relative levels of p-MAPK and Akt did not differ between cells treated with rhSCF1–141 and rhSCF1–165. Relative MAPK expression was significantly higher in cells treated with rhSCF1–165 than in those treated with rhSCF1–141 at concentrations of 0, 10, 20, and 100 ng/mL, and the relative levels of p-Akt were significantly higher in cells treated with rhSCF1–165 than those treated with rhSCF1–141 at concentrations of 20, 100, and 500 ng/mL. These results indicate that rhSCF1–165 treatment affected the expression of MAPK and the phosphorylation of Akt to a greater extent than did rhSCF1–141.

We observed that purified or culture supernatant of P. pastoris-derived SCF1–141 appeared as double bands in silver staining or western blot analysis (Fig. 1C or 1D). The double band might be caused by differential glycosylation or non-glycosylation form of the SCF protein. Such an effect could be confirmed in future studies by deglycosylation enzyme treatment. In a preliminary test, we observed the greatest difference in cell viability (Figure 2) at a concentration of 100 ng/mL of SCF. We then designed a series of thermostability experiments that included a fixed concentration of SCF (100 ng/mL), fixed time (10 minutes), and different incubation temperatures (25, 50, 70, 90, and 110°C). For treatment with either rhSCF1–141 or rhSCF1–165, incubation at 25–70°C for 10 minutes did not decrease cell viability. However, at temperatures of 90–110°C, cell survival rates gradually declined with increasing temperature. Cell survival rates were higher after treatment with rhSCF1–165 than with rhSCF1–141, regardless of temperature. For the short heating time of 10 min, rhSCF1–165 appears to be more heat-stable than rhSCF1–141. At a fixed concentration (100 ng/mL) and temperature (90°C), incubation of cells with either rhSCF1–141 or rhSCF1–165 for 0–30 min resulted in cell viabilities similar to those observed with non-heated SCF. When the heating time was extended to 30–150 minutes, the cell viability decreased significantly.
viabilities decreased to those observed without SCF treatment (control group, 100% survival). Together, these results demonstrate that both full-length soluble SCF1–165 and truncated SCF1–141 enhance cell viability, but SCF1–165 seems to be more stable than SCF1–141. We speculate that SCF activity remained after heating because the two intrachain disulfide bonds in the SCF monomers that maintain biological activity were not disrupted by heating, suggesting that beside S-S bond, the C-terminus also contributes to the thermal stability of SCF.

In this study, we also investigated the effects of heat on SCF structure using CD spectroscopy and limited proteolysis. Protein molecules have aromatic amino acids whose cyclic structures absorb UV light (λ = 100 nm–400 nm). The degree of circularly polarized light absorption depends on the wavelength of light and is affected by the secondary structure of the protein. Thus, CD
scanning of a protein at different wavelengths of light generates a spectrum that can be used to determine its secondary structure. We observed that the CD spectra of rhSCF1–165 that was heat-treated at 70°C for 10 min and at 90°C for 15, 30 and 60 min were identical at 195 nm, the wavelength characteristic of the β-sheet spectrum [29,30]. The shapes of these bands at 195 nm were also similar to that of the unheated control. Conversely, rhSCF1–141 treated at 90°C for 15 or 30 minutes had negative bands at 195 nm, suggesting that the β-sheet structures had changed as a result of thermal denaturation. These results indicate that the secondary structure of SCF1–165 was more thermally stable than that of SCF1–141. Similarly, heat treatment of rhSCF1–141 affected its susceptibility to proteolytic digestion to a greater extent than that of rhSCF1–165, indicating that SCF1–141 is more heat labile than SCF1–165 (Figure 7). Furthermore, the change in the alpha and beta structures of SCF1–141 owing to its heat treatment can be observed in snapshots of the evolving SCF1–141 structure at different time points at different temperatures.

We used molecular modeling software to predict the RMSD values of the protein based on theoretical chemistry. Again, we found that SCF1–165 had a higher thermal stability than SCF1–141. Based on these results, we speculate that recombinant SCF1–165 had a higher thermal stability than SCF1–141 because the additional 14 amino acids in the C-terminus of SCF1–165 play an important role in the structural stability of the protein. This hypothesis deserves further exploration.

Stem cell factor is a glycoprotein with 3 potential sites of N-linked glycosylation: Asn65, Asn72, and Asn120. We are interested in characterizing the glycosylation state of P. pastoris-derived SCF to determine whether glycosylation is important for the biological function of SCF. In future studies, we will express rhSCF in E.coli and in P. pastoris and compare the glycosylation state and activity between SCF derived from these 2 species.

Author Contributions
Conceived and designed the experiments: YPW WYK. Performed the experiments: MHW YLT CYC CAK. Analyzed the data: YPW LLHH. Contributed reagents/materials/analysis tools: MHW. Wrote the paper: YPW.

References
1. Besmer P, Manova K, Duttlinger R, Huang EJ, Packer A, et al. (1993) The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. Dev Suppl 125–137.
2. Broudy VC (1997) Stem cell factor and hematopoiesis. Blood 90:1345–1364.
3. Broudy VC, Lin NL, Liles WC, Corey SJ, O’Laughlin B, et al. (1999) Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. Blood 94:1979–1986.
4. Hemesath TJ, Price ER, Takeimoto C, Badalian T, Fisher DE (1998) MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391:298–301.
5. Huang E, Nocka K, Beier DR, Chu TY, Buck J, et al. (1990) The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63:225–233.
6. Kuninada T, Lu SZ, Yoshida H, Nishikawa S, Mizoguchi M, et al. (1998) Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med 187:1565–1573.
7. Matsui J, Wakabayashi T, Asada M, Yoshimatsu K, Okada M (2004) Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J Biol Chem 279:18600–18607.
8. van Dijk TB, van Den Akker E, Amelvoort MP, Mano H, Lowenberg B, et al. (2000). Stem cell factor induces phosphatidylinositol 3'-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells. Blood 96:5406–5413.
9. Williams DE, Eisenman J, Baird A, Rausch C, Van Ness K, et al. (1990) Identification of a ligand for the c-kit proto-oncogene. Cell 63:167–174.
10. Witte ON (1990) Steel factor defines new multipotent growth factor. Cell 63:5–6.
11. Lu HS, Clagston CL, Wypych J, Fausett FR, Lauren S, et al. (1991) Amino acid sequence and post-translational modification of stem cell factor isolated from buffalo rat liver cell-conditioned medium. J Biol Chem 266:8102–8107.
12. Jiang X, Gurox O, Mendiaz EA, Stearns GW, Clogston CL, et al. (2000) Structure of the active core of human stem cell factor and analysis of binding to its receptor kit. EMBO J 19:3192–3203.

13. Reber L, Da Silva CA, Frassard N (2006) Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 533:327–340.

14. Kurzrock R (2003) Stem Cell Factor. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RCJ, Gansler TS, Holland JS, Frei EI eds. Holland-Frei Cancer Medicine, BC Decker, Hamilton.

15. Liu H, Chen X, Foci PJ, He X (2007) Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J 26:891–901.

16. Zhang Z, Zhang R, Jouhimami A, Schlesinger J, Kong XP (2000) Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation. Proc Natl Acad Sci USA 97:7732–7737.

17. Langley KE, Mendiaz EA, Liu NL, Narhi LO, Zeni L, et al. (1994) Properties of Variant Forms of Human Stem Cell Factor Recombinantly Expressed in Escherichia colt. Archives of Biochemistry and Biophysics 311:53–61.

18. Lu H, Zang Y, Ze Y, Zhu J, Chen T, et al. (2005) Expression, refolding, and characterization of a novel recombinant dual human stem cell factor. Protein Expr Purif 43:126–132.

19. Arakawa T, Langley KE, Kameyama K, Takagi T (1992) Molecular weights of glycosylated and nonglycosylated forms of recombinant human stem cell factor determined by low-angle laser light scattering. Anal Biochem 203:31–37.

20. Wen TN, Chen J, Lee SH, Yang NS, Shyur LF (2005) A truncated Fibrobacter succinogenes 1,3-1,4-beta-d-glucanase with Improved Enzymatic Activity and Thermostolerance Biochemistry 44(25):9197–9205.

21. Fujinaka R, Nakajima M, Yamamoto T, Nagao H, Yokoi T (2009) In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT)1A9. Drug Metab Pharmacokinet. 24(3):235–244.

22. Kundu S, Roy D (2010) Structural study of carboxylesterase from hyperthermophilic bacteria Geotheillus stearothermophilus by molecular dynamics simulation. J Mol Graph Model. 28(3):826–827.

23. Kundu S, Roy D (2008) Temperature-induced unfolding pathway of a type III antifreeze protein: insight from molecular dynamics simulation. J Mol Graph Model. 27(1):88–94.

24. Aghajanian S, Hovsepyan M, GeogheganKF, Chrumy BA, Engel PC (2003) A thermally sensitive loop in clostridial glutamate dehydrogenase detected by limited proteolysis. J Biol Chem. 278(2):1067–1074.

25. Mikhailov VS, Okano K, Rohrmann GF (2006) Structural and functional analysis of the baculovirus single-stranded DNA-binding protein LEF-3. Virology. 346(2):469–479.

26. Meyer G, Dreser HG (1999) FLT3 ligand inhibits apoptosis and promotes survival of myeloid leukemia cell lines. Leuk Lymphoma 32:577–581.

27. Boissan M, Feger F, Guillotton J, Arock M (2000) c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J Leukoc Biol. 67(2):135–140.

28. Rønnsstrand L (2004) Signal transduction via the stem cell factor receptor/c-Kit. Cell. Mol. Life Sci. 61: 2535–2548.

29. Corrêa DHA, Ramos CHI (2009) The use of circular dichroism spectroscopy to study protein folding, form and function. African Journal of Biochemistry Research 3:164–173.

30. Narhi LO, Wypych J, Li T, Langley KE, Arakawa T (1998) Changes in conformation and stability upon SCF/c-kit complex formation. J Protein Chem 17:367–396.